Frequency, risk factors and prophylaxis of infection in <scp>ANCA</scp>‐associated vasculitis

Kronbichler, Andreas; Jayne, David; Mayer, Gert

doi:10.1111/eci.12410

Cited by 95 publications

(81 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35,36 Early, aggressive treatment of infection and considering the use of PJP prophylaxis is recommended. 30,37,38 Skin and hair Anagen effluvium occurs in 5-30% of patients, and alopecia may be permanent. 39 Hyperpigmentation is rare but can involve teeth, skin, mucous membranes and nails.…”

Section: Infectionmentioning

confidence: 99%

Cyclophosphamide in dermatology

Kim

Chan

2016

Aust J Dermatology

View full text Add to dashboard Cite

Cyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely used to treat malignancies and severe manifestations of various auto-immune diseases. High-dose chemotherapy and continuous daily oral regimens are associated with significant toxicity profiles, but i.v. pulsed regimens have lowered the rates of adverse effects in rheumatological studies. Cyclophosphamide has been shown to be useful in the treatment of severe autoimmune conditions due to its powerful immunosuppressive ability; however, it remains a relatively underused modality in dermatology. This article reviews the current literature on cyclophosphamide and its clinical applications in dermatology.

show abstract

Section: Infectionmentioning

confidence: 99%

Cyclophosphamide in dermatology

Kim

Chan

2016

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…ППн развилась только в 1 случае [38]. Авторы крупного обзора проанализировали инфекционные ослож-нения, возникавшие при лечении ANCA-АВ, и пришли к заключению, что профилактика ППн в период индукцион-ной терапии необходима всем пациентам до тех пор, пока суточная доза ГК превышает 10 мг, а количество CD4+ < 300/ мл [39]. Эксперты EULAR поддерживают профилактику ППн с помощью ко-тримоксазола (800/160 мг через день или 400/80 мг ежедневно) для всех больных с ANCA-АВ, полу-чающих терапию ЦФ при отсутствии противопоказаний [40].…”

Section: профилактика ппн при отдельных рз васкулитыunclassified

Pneumocystic Pneumonia in Rheumatic Diseases: Current Issues in Prophylaxis

Белов¹,

Тарасова²,

Буханова³

2017

Med. sov.

View full text Add to dashboard Cite

“…Although non-inferior in both randomized, controlled trials, adverse events (e.g. serious infections) were comparable [8,9]. In an elegant retrospective study, Besada et al investigated the role of maintenance rituximab treatment.…”

Section: The Nasal Microbiome In Granulomatosis With Polyangiitismentioning

confidence: 99%